Navigation Links
AngioGenex Reviews 2008 Achievements and Sets Goals for 2009
Date:11/25/2008

rtners and investors to support the clinical development of its drugs.

Dr. Garland set out the Company's principal goals for 2009 as follows: "We will conduct additional IND-enabling preclinical studies with AGX51 and present findings from these studies at a major cancer meeting in 2009. The new studies will include expanded safety and additional anti-tumor testing of AGX51 in animals as well as further exploration of the feasibility of use of our companion diagnostic for theranostic purposes. Our goal is to file an IND on AGX51 and to initiate human testing within the next twelve to eighteen months. AngioGenex also plans to recruit at least one new Board member who can help guide the Company's effort to raise additional capital and move its program forward. Raising capital to fund our drug development work will continue to be a central focus of effort in 2009."

Company Profile:

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes or proteins to prevent the formation of new blood vessels into tumors (angiogenesis). The Company's technology is based on the research of Dr. Robert Benezra and his colleagues at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City who established that activation of the Id genes is required for the formation of new blood vessels into tumors, allowing tumors to grow and metastasize. Dr. Benezra demonstrated that the absence of the Id genes in animals results in a highly significant inhibition of tumor growth and a reduction in the size of mature tumors. The research of Dr. Benezra on the role of the Id genes in tumor formation has been widely recognized for its important therapeutic implications.

This press release may contain forward-looking statements that involve risks and uncertainties that could cause actual events or results to diffe
'/>"/>

SOURCE AngioGenex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. William Garland Joins AngioGenexs New Board of Directors
2. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
3. CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market
4. CBDM.T, The Market and Business Intelligence Company Reviews The Biomanufacturing Market
5. Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
6. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
7. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
8. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... that he will lead on “Stem Cells” at the ... in London. In the interview posted online ... to several questions on the current state of technologies for ... and future trends in the use of stem cells for ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... study of single-agent carfilzomib, a next generation proteasome inhibitor, ... achieved an overall response rate (ORR) (partial response or ... response (DOR) of 8.3 months in patients who entered ...
... show scientists the way to make batches of nanotubes of ... Physical Review Letters unveils an elegant formula by ... the energy of a piece of graphene cut at any ... materials science and of chemistry, said this alone is significant ...
... 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... the first 60 patients enrolled in the Phase I/II trial ... reported today in an oral presentation at the 52nd American ... Florida. "Anemia is the most serious symptom associated ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 2Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 3Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 4Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 5Pure nanotube-type growth edges toward the possible 2Pure nanotube-type growth edges toward the possible 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... decades, planetary geologists have speculated that glaciers might ... chasm that constitutes the Grand Canyon of Mars. ... might have been carved by past glaciers as ... have remained highly controversial and contested. , ... and the Freie Universitaet Berlin has identified what ...
(Date:9/29/2014)... found that a combination of a real-time feedback system ... of residence resulted in a reduction of 37% in ... were 1360.49 kWh, which is equivalent to a reduction ... weeks. , In contrast, another eight halls, exposed ... alert, resulted in saw a 3.5% reduction in energy ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... NY-- The Damon Runyon Cancer Research Foundation named ... 2008 Fellowship Award Committee review. The recipients ... scientists conducting basic and translational cancer research in ... country. The Fellowship is specifically intended to ...
... is available in French . , McGill ... of the world leading pioneers in green chemistry, an entirely ... toxic, petrochemical-based solvents in favour of basic substances like water ... of the green approach are obvious and significant, but following ...
... Industry scientists and international collaborators have discovered the key ... years cost wheat growers worldwide in excess of AUS$7.8 ... prestigious journal Science , scientists from CSIRO Plant ... and Wheat Improvement Center have identified a wheat gene ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 4Peptides-on-demand: McGill researcher's radical new green chemistry makes the impossible possible 2Saving wheat crops worldwide 2
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Request Info...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
Biology Products: